Glenmark USA launches Lacosamide Oral Solution, 10 mg/mL
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
Lacosamide is indicated to treat partial-onset seizures
Lacosamide Injection is used to treat partial-onset seizures.
According to IQVIA sales data for the period ending January 2022, Vimpat tablets market achieved annual sales of approx. US $ 1.7 billion
The company plans to launch the product immediately
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
Subscribe To Our Newsletter & Stay Updated